Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
WEE1, the founding member of the WEE kinase family, has been implicated in over a dozen cancer types. This has led to extensive efforts to develop inhibitors; for example, adavosertib (AZD1775), a leading selective WEE1 inhibitor, has been tested as a single agent and in combination in more than 50 clinical trials in patients with cancer. So far, however, another member of the family, PKMYT1 has been largely ignored, although it shares a high degree of functional redundancy with WEE1 and so could also represent a promising and tractable target.
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery19, 157 (2020)
doi: https://doi.org/10.1038/d41573-019-00202-9
Acknowledgements
This article is part of a series from the NIH Common Fund Illuminating the Druggable Genome (IDG) program. The goal of IDG is to catalyse research on understudied proteins from druggable gene families by providing reagents, phenotypes and a mineable database, focusing on GPCRs, kinases and ion channels.